As of May 27, 2025, Eagle Pharmaceuticals Inc (EGRX) reports a ROA (Return on Assets) of 8.76%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Eagle Pharmaceuticals Inc's ROA (Return on Assets)
Over recent years, Eagle Pharmaceuticals Inc's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2022-12-31 | 8.76% |
| 2021-12-31 | -3.39% |
| 2020-12-31 | 4.74% |
| 2019-12-31 | 5.62% |
| 2018-12-31 | 13.37% |
This slight downward trend highlights how Eagle Pharmaceuticals Inc manages its efficiency in using assets to generate earnings over time.
Comparing Eagle Pharmaceuticals Inc's ROA (Return on Assets) to Peers
To better understand Eagle Pharmaceuticals Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Eagle Pharmaceuticals Inc (EGRX) | 8.76% |
| MEI Pharma Inc (MEIP) | 42.97% |
| Intercept Pharmaceuticals Inc (ICPT) | 40.06% |
| Catalyst Pharmaceuticals Inc (CPRX) | 19.25% |
| MiMedx Group Inc (MDXG) | 16.07% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
Compared to its competitors, Eagle Pharmaceuticals Inc's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.